StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

Equities research analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

Shares of BPTH opened at $0.18 on Friday. Bio-Path has a one year low of $0.12 and a one year high of $7.67. The business’s 50 day simple moving average is $0.75 and its 200-day simple moving average is $0.89.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.